Background: Orthopaedic surgery in RA is considered a surrogate marker for joint destruction. It has been postulated that the need for orthopaedic surgery would be reduced with greater use of more intense therapies for RA. We were able to examine this proposal in two UK multicentre inception cohorts conducted between 1986 & 2011. Methods: The Early RA Study (ERAS) recruited from 1986-1999 (n ¼ 1465) , the Early RA Network (ERAN) from 2002 (n ¼ 1236). Symptom onset to baseline was median 6 months in both and time to 1st DMARD was median 2 & 1 month respectively. Standardized clinical, laboratory and x-ray measures were performed yearly in both cohorts. Disease-modifying, steroid and biologic therapies reflected conventional practice and guidelines of the time frames examined. Source data of all orthopaedic interventions included clinical datasets (patient report and medical records from 1986), which were validated with Hospital Episode Statistics (HES from 1997) and the National Joint Registry (NJR from 2002). Length of follow up was based on the National Death Registry. Results: In ERAS 558 patients (38%) had 1287 orthopaedic procedures over a maximum of 25 years follow up. 18.5% had major (e.g. total joint replacements), 16% had intermediate (e.g. wrist synovectomy, forefoot arthroplasty), and 17% minor (e.g. carpal tunnel release). In ERAN (max 9 years follow up) 216 patients (17.5%) had 326 procedures, 7% major, 3.4% intermediate, 9% minor. Graphic displays will show that secular declines in combined major/intermediate surgical rates were seen from 1987-2011 (18 to 16 per 1000 patients/year), coinciding with use of more intensive combination and biologic therapies. Declines were mainly in intermediate type surgery of wrist, hands and feet (8 to 6 per 1000 patients/ year) and not in total joint replacements (mainly hip & knee). Risk factors were also different for the two surgical groups. In univariate analysis, women had increased risk for intermediate surgery only (odds ratio 3.2, CI 2.21-4.7). Baseline and 1year DAS, HAQ, ESR, Haemoglobin(HB) and erosions all predicted 5 & 10 year major and intermediate surgery (ORs all significant around 1.5-2). Low HB predicted a subgroup who had multiple joint surgery by 5 & 10years (OR 2.6, CI 1.5-4.4 and OR 3.0, CI 2.1-4.4 respectively). In Cox regression, sex, onset age and erosions predicted intermediate surgery, and sex, onset age and HB predicted major surgery. Conclusions: Orthopaedic surgery is an important and common outcome in RA by 10 years, not often reported and difficult to predict. Only hand/foot surgery rates showed a consistent decline from 1986-2011, suggesting a different pathology or response to therapy between large and small joint destructive processes. HB does not normally Background: Anti-TNFa therapies are highly effective in the treatment of rheumatoid arthritis (RA) but a significant proportion of patients have an inadequate response. Given the important role of TNFa in regulating systemic and localized metabolism, we sought to determine if the metabolic profile of patients prior to therapy could be used to predict responses to anti-TNFa agents. Methods: Urine was collected from 16 patients with RA before and during therapy with infliximab or etanercept as part of a multicentre study. All patients were female and the mean age was 51.5. 14 patients were positive for rheumatoid factor and 14 for the anti-CCP antibody. All patients had a DAS28 > 4 at baseline. Urine metabolic profiles were assessed using NMR spectroscopy. The relationship between metabolic profiles and clinical outcomes was assessed (using partial least square discriminant analysis (PLSDA), Galgo and PLS-R analysis) and relevant metabolites were identified (using metabolite databases and Chenomix). Results: Baseline urine metabolic profiles were able to discriminate between RA patients who did (7 patients) or did not (9 patients) have a good response to anti-TNFa therapy according to EULAR criteria with a sensitivity of 85.9% and specificity of 85.7% with several metabolites (in particular citrate, creatinine and cresol) contributing. There was a significant correlation between baseline metabolic profiles in the urine samples and the extent of change in DAS 28 (PLS-R analysis p ¼ 0.04). In patients with RA who responded to TNFa antagonists, a good response to therapy was associated with changes in the following urinary metabolites: erythritol, phenylacetic acid, cresol, propionic acid, methylamine, citrate, hippuric acid and creatinine. Urine samples were also available for 20 patients with psoriatic arthritis (PsA). Similar metabolites were identified in the urine samples of the patients with PsA that responded to TNFa antagonists. We were unable to study the ability of baseline urinary metabolite profiles to predict response in PsA as all but one of the PsA patients responded according to predefined criteria. Conclusions: There are clear differences in the metabolic profiles of baseline urine samples of RA patients who go on to respond well to anti-TNFa therapy. This may be relevant in the development of clinically useful predictive strategies. Background: In a proof-of-concept study, secukinumab showed rapid and significant improvement of signs and symptoms in rheumatoid arthritis (RA) patients relative to placebo, We assessed efficacy and safety of secukinumab in RA patients despite stable methotrexate (MTX) up to Week (wk) 52. Methods: Adult RA patients (n ¼ 237) on MTX were randomized equally to receive monthly s.c injections of secukinumab 25 mg, 75 mg, 150 mg, 300 mg or placebo. After wk16, responders on secukinumab remained on the same dose whereas doses were escalated in nonresponders at wk20 (except patients initially on 300 mg who remained on the same dose). All placebo patients were switched to secukinumab 150 mg. Patients were followed up to wk52. Primary endpoint was the proportion of patients achieving American College of Rheumatology (ACR) 20 at wk16. Results: Demographics and baseline characteristics were comparable across all groups. At wk16 ACR20 responders were higher with secukinumab 75 mg, 150 mg and 300 mg vs placebo (47%, 47% and 54% vs. 36%) but did not reach statistical significance. Responders on secukinumab at wk 16 maintained their ACR responses through wk52; for the 25 mg, 75 mg, 150 mg, 300 mg cohorts ACR20 responses were 67%, 57%, 90% and 71%, respectively. Highest responses in ACR50/ 70 responses at wk24 and wk52 were seen in patients who remained on secukinumab 150 mg for the entire study (wk24: ACR50 ¼ 50%, ACR70 ¼ 20%; wk52: ACR50 ¼ 55%, ACR70 ¼ 40%). DAS28-CRP reductions were sustained up to wk52 in responders on secukinumab 150 mg along with improvement in HAQ scores (-0.6 ¼ wk24 vs À0.8 ¼ wk52) and EULAR remission rates (DAS28-CRP 2.6: 30% ¼ wk24 vs 40% ¼ wk52). Non-responders did not gain much additional efficacy benefit after dose escalation as assessed by ACR20/50/70 and DAS28-CRP. The overall rates of AEs from wk20 -60 were comparable to those observed up to wk20 (60-70%) and most AEs were mild to moderate in severity and did not lead to study discontinuation. Between wk 20 -60 the rate of infections was 31.9% with six infections reported as SAEs. A total of 28 SAEs were reported in 21 patients. In this period, three malignancies and no deaths were reported. Conclusions: The primary efficacy endpoint was not achieved in this study. ACR20 responders at wk16 showed sustained improvement of efficacy through wk52 with highest efficacy in patients who remained on 150 mg throughout the study. DAS28-CRP and HAQ scores improved through week 52 in responders who remained on secukinumab 150 mg. There were no safety signals with secukinumab related to specific organ class and the rate and frequency of AEs remained stable over time with no unexpected safety findings. 
for an additional 52 wks (P2). Clinical, radiographic, and functional outcomes were evaluated. Logistic regression was used to determine baseline (BL) predictors of stable composite outcomes (DAS28 < 2.6 or SDAI 3.3, and HAQ < 0.5, and ÁmTSS 0.5 from wks 52-78) in ADA þ MTX(R)!PBO þ MTX pts. Pts were monitored for adverse events (AEs). Results: Of 466 ADA þ MTX pts completing P1, 207 (44%) achieved the stable LDA target and were re-randomized to ADA þ MTX(R) Background: With population ageing there is a growing drive to promote a healthier old age and ways to age successfully. Successful ageing is a multi-faceted state, which involves preservation of biomedical, physical, psychosocial and lay components to enable cognitive, physical and mental well-being, social participation and quality of life. Musculoskeletal pain is common in older adults and is considered as a stressor which impacts on a number of body functions. This is the first longitudinal study to investigate the relationship between musculoskeletal pain and successful ageing in the general population. Methods: Population-based prospective cohort study of adults aged 50 years and over, the North Staffordshire Osteoarthritis project was conducted. Subjects were those who had completed questionnaires at baseline, 3 and 6-year follow-ups. Based on their reports of pain, subjects (n ¼ 2949) were classified into those reporting no, regional and widespread pain (ACR criteria). Using published methodology a 33-item successful ageing index (SA) was constructed by summing the number of deficits across biological, psychological and functional domains. SA scores were calculated for each subject at baseline, 3 and 6 years by dividing the number of deficits by the total number of potential deficits and was expressed as a score from 0 to 100. Linear regression models were used to test the association between SA in each time point and pain status at baseline. Mixed modelling was used to explore the longitudinal trends in SA across six years; pain was included as a time varying variable to examine the impact of change in pain status on SA. These associations were then adjusted for potential confounders: gender, education and baseline social networks, use of analgesia and diagnoses of chronic musculoskeletal conditions (osteoarthritis and inflammatory arthropathies). Results: Median age of subjects was 61 (IQR: 55 to 67). 54% were female. At baseline 834 (28.7%) had no pain, 1296 (44.5%) had regional pain and 780 (26.8%) had widespread pain. Baseline regional and widespread pain were associated with higher SA scores at all three time points (p < 0.05); those with widespread pain had the highest scores. Increasing pain was associated with increasing SA scores over time; an increase from none to regional and regional to widespread pain resulted in a 19% and 17% increase in SA scores respectively. An increase from none to widespread lead to a 40% increase in SA score. Adjustment for diagnosed musculoskeletal conditions and analgesic use had little effect on the impact of pain on increasing SA scores.
Conclusions:
The results indicate that pain has a significant adverse affect on successful ageing. At baseline, individuals with regional and widespread pain had accumulated significantly more signs of less successful ageing than those with no pain. The longitudinal results indicate that increasing pain significantly accelerates the rate of less successful ageing, independent of diagnoses and analgesia. Disclosure statement: All authors have declared no conflicts of interest. Background: Foot complications represent a significant burden to patients with RA in terms of pain, but also because of the disabling nature of impaired mobility. There is limited evidence to suggest which patients may go on to experience the greatest burden of disability and what factors may be clinically relevant treatment targets in the prevention and management of such cases. Thus, the study aim was to determine the natural history of foot related disability in patients with RA. A secondary aim was to identify potential explanatory variables either associated with or predictive of disabling foot complications in patients with RA. Methods: Patients with RA were consecutively, prospectively recruited from a Southampton rheumatology outpatient clinic. Data collection was completed at baseline (N ¼ 149), one-year (n ¼ 120) and three-year follow-up (n ¼ 60). Patient-reported disabling foot complications were evaluated using the two subscales of the Foot Impairment Score; foot impairment/footwear restriction (FISIF) & activity limitation/participation restriction (FISAP), and a visual analogue scale of overall wellbeing. Explanatory variables investigated included ultrasound detectable forefoot pathology and markers of disease activity. The main statistical methods used were multiple linear regression and tests of linear association (Pearson's Correlation coefficient; PCC). Results: Overall patient-reported disabling foot complications were highly prevalent across all time points (Table 1) Background: Musculoskeletal health care professionals have expressed concern at the increased difficulties in undertaking continuing professional development (CPD). CPD includes 'a wide range of learning activities through which professionals maintain and develop throughout their career to ensure that they retain their capacity to practise safely, effectively and legally within their evolving scope of practice'. It is conducted to 'provide the best possible care for patients' and can include formal or informal activities. CPD is a requirement in many countries for nurses and AHPs, although recommendations for the time spent on CPD varies, from no specific time requirements for UK AHPs to 35 hours over three years for UK Nurses. Methods: This electronic survey explored the current UK status of CPD, for nurses and AHPs working in musculoskeletal services. It formed the second phase of a two part research project funded by Arthritis Research UK. The first phase used three focus groups and two telephone conference calls to explore patients, clinicians and managers experiences of CPD within MSK services. These findings informed the content and development of this electronic questionnaire survey. The survey was designed using Question Mark Perception, administered from the University of Southampton and distributed via professional bodies and BHPR. Results were collected online and analysed in SPSS PASW 17 using frequency data and 2 analyses. Results: 354 responses were analysed, (51.7% physiotherapists; 30.2 % occupational therapists; 9.9% podiatrists; 7.3% nurses; 0.9 % other). 63.8% of responders worked exclusively in the NHS. 81% worked in England, 14% in Scotland; 4% in Wales and 2% in Northern Ireland. 84% of respondents had more than five years' experience working with patients who have musculoskeletal conditions.
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The most frequent reported reasons for undertaking CPD was to improve patient care (56%) maintenance of clinical skills (37%) and to stay up to date (28%). The majority of respondents reported that their organization was supportive of CPD activities and in applying new knowledge to practice (86%) however, the most frequently reported barriers to CPD included lack of funding (78%) and within this group 24% reported no available CPD funding. 68% reported having too many other tasks including meeting productivity targets and 42% reported that they could only ''sometimes or never'' secure CPD study leave. There were no statistically significant differences in seniority level nor employment sector in accessing CPD opportunities.
Conclusions:
The results indicate that despite the organizational support for CPD respondents faced substantial challenges accessing CPD when under pressure to achieve productivity targets, with little assistance in terms of funding. This discrepancy may indicate that greater support is required for musculoskeletal nurses' and AHPs' CPD needs. Background: Foot pain is common in rheumatoid arthritis (RA). Symptoms often occur, due to hard callus arising as a result of increased pressure over the plantar metatarsal head. Sharp scalpel debridement of painful plantar callosities is a standard treatment to relieve discomfort but it carries risks of haemorrhage, ulceration and introduction of infection. Furthermore, debridement is rarely the sole course of treatment; functional orthotic therapy and footwear advice/ provision may also be used. Recently, the short-term benefits of callus reduction for people with RA were called into question. Methods: 65 patients with RA and presenting with painful forefoot plantar callosities for the first time were randomized to receive one of two treatment protocols. The treatment arm comprised regular debridement of painful forefoot plantar callosities in conjunction with mechanical interventions (e.g. orthoses, footwear) while the control arm comprised mechanical interventions alone. The primary outcome was a reduction in pain on a 100 mm visual analogue scale. Secondary outcomes included health status (Leeds Foot Impact Scale, a diseasespecific scale for measuring the impact of foot disease in 2 domains: impairment/footwear (LFIS IF ) and activity/participation (LFIS AP )), ambulatory function (velocity measured by GAITRite) and complication rates (ulceration, infection). Patients were followed up for 18 months. Results: The mean baseline and 18 month follow-up pain scores were 40.8 and 22.3, respectively, for the treatment group and 53.4 and 34.0, respectively, for the control group. There was no difference between groups in the primary outcome of pain, allowing for differences in baseline scores (F ¼ 1.2, p ¼ ns). Mean baseline and follow-up GAITRite velocity scores were 90.1 and 89.8 cm/sec for the treatment group and 85.7 and 88.5 cm/sec for the control group. In the treatment group, mean baseline LFIS IF score was 12.2 and follow-up was 11.3, mean baseline LFIS AP , was 15.3 and follow-up was 15.7. In the control group, mean baseline LFIS IF score was 14.1 and follow-up was 13.2, mean baseline LFIS AP , was 18.0 and follow-up was 16.1. Secondary outcomes of health status and ambulatory function also showed no differences between groups. Complication rates were infrequent in both groups. Conclusions: Sharp scapel debridement of painful forefoot plantar callosities in conjunction with mechanical interventions in RA reduced pain, but the effect was no different from the use of mechanical interventions alone. The long-term outcomes were consistent with previous study findings and further question the efficacy of sharp scapel debridement of painful forefoot plantar callosities in people with RA. Background: Exercise is important in the management of RA. Our research has indicated that RA patients perceive health professionals (HPs) lack certainty and clarity about exercise in RA management and its relationship to joint damage (Law et al., 2010) . Furthermore, our questionnaire study of rheumatology HPs suggested that perceptions of HPs and patients are not congruent (Halls et al., 2011) . We therefore set out to further explore HPs' perceptions regarding the effects of exercise on joint health in RA patients' using focus groups. Methods: Four moderated focus groups were conducted with multidisciplinary teams (MDTs) of rheumatology HPs (n ¼ 24; 19 females, 5 males; 5 rheumatologists, 8 nurses, 5 physiotherapists, 4 occupational therapists, 2 other HPs; age: 30 -60 years; duration working with RA: 3 -32 years) from across the North-West United Kingdom. The main questions addressed included: (i) What are your thoughts about exercise and joint health in your RA patients? (ii) What do you tell your RA patients about exercise? and (iii) Why do the perceptions of patients and HPs differ? Focus group recordings were transcribed verbatim and transcripts were analysed using framework analysis. Discussion with three associated researchers consolidated validation at different stages of analysis. Results: Focus group analysis identified twenty one constructs and five themes as factors relating to HPs' perceptions of exercise and joint health in their RA patients. The five emergent themes were: 'Exercise is beneficial', 'Concerns about damage to joints', 'Patients have barriers to exercise', 'HP knowledge differs' and 'Patients may think service delivery is vague'. Conclusions: HPs articulated acute awareness of the benefits and importance of exercise for RA patients. Concerns regarding exercise, particularly weight-bearing exercise, were expressed explicitly, as well as indirectly, which could lead to confusion for RA patients. The perceived lack of a solid evidence base was highlighted as a reason for these concerns. Moreover, the complexity of RA treatment and management was felt to negatively impact the likelihood of exercise prescription. When managing RA, HPs provide individualized care and promote self-management. These issues may explain why patients perceive their MDTs lack certainty and clarity about exercise in RA management and its relationship to joint damage. Further research is warranted to address the uncertainties of HPs regarding exercise and joint health. Table 1 shows the prevalence of each MetS component over time in those with MetS data. Whilst the prevalence of elevated waist circumference and blood pressure remains stable, the prevalence of both elevated glucose and triglycerides fell over time. Conclusions: MetS was common in this cohort of young, predominantly female, patients with recently diagnosed SLE. Overall, 27% had MetS on at least 1 occasion during the first 2 years of follow-up. Certain components of MetS vary over time in SLE patients and may be more responsive to changes in inflammatory disease burden and exposure to therapy. Background: Many different autoantibodies have been described in patients with SLE and serological assays have concentrated mainly on measuring autoantibody levels. Measuring levels of modified autoantigens may also be valuable. Nucleosomes from apoptotic debris are known to play a key role in pathogenesis of SLE, especially lupus nephritis. Nitration of histones within nucleosomes may be enhanced in patients with SLE by the presence of increased serum levels of reactive nitrogen species characteristic of inflammatory states. We developed a novel assay for measuring serum nitrated nucleosome (NN) levels. Here we report on results of this assay in patients with SLE and associations with ethnicity, autoantibody profile and measures of disease activity in patients with SLE. Methods: Multiple stored serum samples (mean 8 per patient) from a cohort of 49 patients with SLE were tested. The samples had been obtained over a mean (SD) follow-up period of 89 (46) months. NN levels were measured using a novel capture ELISA: serum added to a streptavidin plate pre-coated with a biotinylated anti-nitrotyrosine antibody followed by detection with a rabbit anti-histone-3 antibody and then an anti-rabbit IgG HRP conjugated antibody. OD values were converted to standard absorbance units (AU) by comparison to a positive control sample loaded on every plate. The mean absorbance value for each of the patients was calculated. Univariate analysis was used to investigate association between these levels and age, gender, ethnicity, disease duration, autoantibody status and disease activity. For all samples where data were available, we obtained anti-dsDNA and complement C3 levels and disease activity from a matching date and from the previous 3 assessments if these had occurred in the preceding 12 months. Using the British Isles Lupus Assessment Group (BILAG) index, we categorized the samples by disease activity as follows. Current activity (on the date of the sample) was defined as high if global BILAG score was !5 and low if it was <5). Disease activity over the most recent 4 assessments was characterized as persistently low activity (all systems BILAG C, D or E) or persistently moderate-high activity (A or !1 B in any BILAG system on at least 2/4 occasions). 90% of all samples fell into one of those two categories and the rest were excluded. Anti-dsDNA was defined as high or normal based on a cut-off of 50 IU/ml. C3 was defined as low or normal based on a cut-off of 0.9 g/l.
Results: The assay yielded reproducible results with an intra and inter-plate coefficient of variation of <10%. The mean age of the patients was 36 years (SD 13) and 81% were female. 23 were Caucasian, 18 Afro-Caribbean (A-C) and 8 other ethnicities. 17 patients had no NN at any time-point. In the other 34 patients, NN levels varied over time (mean 32.4 AU; SD 62.2; min 0; max 270.4). Age, gender and disease duration were not associated with NN level. A-C patients had significantly higher NN than other ethnic groups (p ¼ 0.03). Anti-Sm positivity was strongly associated with higher NN levels. Mean NN was 103.5 AU in anti-Sm positive and 7.75 AU in antiSm negative patients (p < 0.0001). The apparent effect of ethnicity may be mediated via anti-Sm positivity since A-C patients were significantly more likely than other ethnic groups to be anti-Sm positive (p ¼ 0.04) and within the A-C group, anti-Sm positive patients had significantly higher NN levels than anti-Sm negative patients (p ¼ 0.0004). There was no relationship between NN levels and positivity for anti-La, antiRo, anti-RNP or antiphospholipid antibodies.
As shown in table 1, higher NN levels were significantly associated with current and persistently high activity, low C3 and high antidsDNA. In addition, we categorized the samples in terms of activity in individual systems. The highest mean NN levels were seen in patients with neuropsychiatric flares (n ¼ 18, NN ¼ 54.9) and general flares (n ¼ 31, NN ¼ 50.3) whereas the lowest were seen in those with mucocutaneous (n ¼ 41, NN ¼ 26.2) and cardiovascular (n ¼ 13, NN ¼ 23.2) flares. Conclusion: NN were found in the serum of 65% of patients with SLE. Anti-Sm positivity and Afro-Caribbean ethnicity were associated with significantly higher NN levels. High NN levels were also associated with high disease activity, high anti-dsDNA and low complement. In addition, flares in different organ systems may be associated with different levels of NN. Background: Bosentan monotherapy is a commonly used first line therapy in systemic sclerosis associated pulmonary arterial hypertension (SSc-PAH) but there is limited data on survival in this rare patient group. Some case series have suggested a possible survival benefit in patients with idiopathic pulmonary arterial hypertension who are treated with warfarin, however little is known about its effect in patients with SSc-PAH. By studying a well defined patient cohort treated with the same PH-specific therapy, we hoped to identify whether warfarin treatment was associated with improved survival. Methods: A retrospective analysis of consecutive patients with newly diagnosed SSc-PAH at a large regional centre from 2003-July 2010. Inclusion criteria were: systemic sclerosis and treatment naïve PAH (mPAP !25 mmHg, PCWP 15) when starting bosentan monotherapy. Patients with evidence of significant interstitial lung disease on imaging (HRCT) or lung function tests (FVC < 70%) were excluded. Survival distributions were measured using Cox-Mantel log rank test. KaplanMeier survival estimates were used to investigate the influence of variables on survival. Results: 125 patients were identified. The mean age was 63 (range 23-85) and 88% were female (ratio F:M 7.3:1). Disease subtype was LcSSc in 116 patients (93%) and DcSSc in 9 patients (7%). Mean haemodynamic values at initial right heart catheterization were mPAP 40 mmHg and PVR 580 dyns.s.cm-5.
Univariate cox regression analysis showed the following factors were not associated with survival: gender (p ¼ 0. On multivariate analysis after adjustment for age, disease subtype, gender and WHO functional class warfarin remained the only significant prognostic factor (HR 0.50 p ¼ 0.048 95%CI 0.026-0.99). Kaplan-Meier survival estimates showed that warfarin was associated with a improved survival (Log-rank p ¼ 0.0068.) Conclusions: We present a novel finding, that warfarin treatment is associated with a dramatically improved survival in SSc-PAH patients treated with first line bosentan monotherapy. The benefits associated with warfarin may be due to unmeasured confounders, its effect on the disease or interactions between the drugs. Ideally, a randomized controlled trial is required to investigate with the association is causal. Disclosure statement: J.C. has received staff support, consultancy fees, lecture fees and research grants from Actelion, GSK, Pfizer, and consultancy fees and lecture fees from Bayer and Ely Lilly. C.D. has received speaker fees from Pfizer, Actelion and GSK, and consultation and research grants from Pfizer and Actelion. C.H. has received education and travel grants from Actelion and. B.S. has received educational and travel grants from Actelion and GSK, and speaker fees from Actelion. All other authors have declared no conflicts of interest. Background: Positive anti-nuclear autoantibodies (ANAs) occur in 75-95% of Systemic Sclerosis (SSc) patients. The specific SSc autoantibodies (anti-centromere, anti-topoisomerase-1, anti-RNA polymerase III, anti-U3RNP, anti-U11/U12 RNP and anti-To/Th) have been shown to correlate with distinct clinical subsets of patients. Other SSc related autoantibodies (PmScl, Ku, Ro60, La and U1RNP) can be found in a variety of other connective tissue diseases and in SSc patients with overlap features. Despite this vast array of autoantibodies, there remains a group of SSc patients that still appear autoantibody negative. Here we report a new autoantibody in seven patients with SSc. Methods: Serum and clinical data were collected from 379 patients with SSc investigated for interstitial lung disease and a separate 169 unselected SSc patients. Serum was also available from a control population consisting of 171 patients with other forms of connective tissue disease (dermatomyositis, polymyositis, systemic lupus erythematosus and rheumatoid arthritis), 141 patients with idiopathic interstitial lung disease and 88 healthy normal controls. All sera were tested by routine serological techniques followed by radiolabelled protein immunoprecipitation (IPP) for those samples negative for the most common SSc-related autoantibodies, anti-centromere, anti-topoisomerase 1 and anti-RNA polymerase III autoantibodies. Patients' sera that immunoprecipitated a novel 30 kDa band were further analysed by indirect immunofluorescence and IPP using depleted cell extracts to establish a common reactivity. A combination of nonradiolabelled IPP and mass spectrometry (MS) was used to identify the novel autoantigen and findings were confirmed using both immunodepletion and IPP-western blotting using commercial antibodies.
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Results: A novel autoantigen with an estimated molecular weight of 30 kDa was recognized by 7 sera with SSc, 6 of whom had confirmed interstitial lung disease, and by no controls. The seventh novel autoantibody-positive patient did not have a chest CT but had a reduced pulmonary gas transfer. Six of the patients had diffuse cutaneous involvement and four had overlap features with other autoimmune diseases (two polymyositis and two RA). None of the seven sera contained other known autoantibodies. Immunodepletion experiments indicated that all seven serum samples immunoprecipitated the same autoantigen and MS analysis identified the novel autoantigen as EIF2 (Eukaryotic Initiation Factor 2). These findings where confirmed by both immunodepletion and immunoprecipitation western blotting using commercial anti-EIF2 antibodies.
Conclusions: We report a novel autoantibody (anti-EIF2) found in a small number of patients with SSc (approximately 1%) that appears to be specific for SSc / SSc-overlap and closely associated with the presence of interstitial lung disease. Our findings emphasize the close association between SSc and the development of disease-specific autoantibodies. Background: Skin involvement in systemic sclerosis (SSc) is often primary outcome in clinical trials but it is still orphan of a quantitative imaging technique. Optical Coherence Tomography (OCT) is an emerging imaging technology for clinical examination employing a low-intensity infra-red laser beam and providing high-contrast 2 mm deep skin images with a 4 micron resolution. The purpose of this study was to evaluate face validity of OCT in scleroderma. Methods: Dorsal aspect of forearms was assessed in this study employing topical probe ''VivoSight'' (Michelson Diagnostics) and optics of Swept-source Fourier-Domain type with a laser wavelength of 1305þ/-15 nm. A 4 mm area was scanned with 100 scans each of 4 micron thickness. Clinical skin involvement was determined using the modified Rodnan skin score (mRSS). The study included 5 forearms scored as ''3'', 5 scored as ''0'' and 5 from healthy controls. Matlab software was employed to calculate mean density of the scans. Haematoxylin-Eosin (H&E) staining was performed from forearm skin biopsy, within 1 cm of OCT scanned region, in two SSc patients. Results: OCT images collected in healthy volunteers showed, consistently with published findings, a regular hyper-reflective border of the skin surface (4 micron) and a homogeneous hypo-reflective epidermal layer (60 micron). The papillary dermis was consistently visualized as hyper-reflective area compared to the adjacent epidermis allowing the visualization of the dermal-epidermal junction (DEJ). Mean Optical Density (OD) data showed that DEJ was a OD nadir region between 60 and 70 micron from the surface, the papillary dermis a high density region (OD range: 0.64-0.72; micron range: 60-100) and the reticular dermis had a OD ranging from 0.72 and 0.4. In contrast SSc affected tissues (mRSS ¼ 3) showed no DEJ and no increase in OD in the papillary dermis which appeared with a range density of 0.61-0.56. Interestingly the OD range of this area was almost normal in patients with mRSS ¼ 0 (OD ¼ 0.64-0.67). Validation with H&E staining of 2 SSc patients with mRSS ¼ 3 in the target region, confirmed the localization of the above mentioned density areas. Conclusions: This is a proof-of-concept validation of face validity of OCT as quantitative imaging technique of scleroderma skin. Sensitivity to change ability of OCT is under evaluation to determine whether the technique could be used as outcome measure of skin involvement in SSc. Disclosure statement: All authors have declared no conflicts of interest. Background: Primary Sjö gren's syndrome (pSS) is a multi-system autoimmune disease. Anti-Ro is the most commonly associated antibody. This can be differentiated into two subtypes, anti-Ro52 and anti-Ro60, each specific to different antigens. Clinical associations of the subtypes remain controversial in pSS. The UKPSSR is a large national cohort and biobank of over 600 clinically well characterized patients with pSS. All data and samples have been collected prospectively using a standardized proforma as previously described [1] , providing a unique opportunity to explore whether anti-Ro52 and anti-Ro60 are associated with distinct clinical manifestations in pSS. Methods: Serum anti-Ro 52 and anti-Ro60 levels were measured using a high sensitivity Phadia assay on 314 UKPSSR patients as part of the interim analysis. Patients were stratified according to the presence of anti-Ro52 or anti-Ro60 and the relationship between these antibodies and clinical manifestations of pSS were examined. The EULAR Sjogren's syndrome disease activity index (ESSDAI) was used as the basis for stratification of involvement of different organs. Differences between groups were tested using Chi-squared and Mann Whitney U tests for categorical and non-parametrical data respectively. Results: Anti-Ro52 was positive in 81% of patients and anti-Ro60 in 82%. 8 (2.5%) patients were positive for anti-Ro-52 but not anti-Ro-60, 10 (3.1%) patients were positive for anti-Ro-60 but not anti-Ro52, and 49 (15.6%) patients were negative for both antibodies. There was a significant association between anti-Ro52 and disease activity in the biological (RR ¼ 4.6, 95% CI: 2.3, 9.2; p < 0.0001) and articular (RR ¼ 0.7, 95% CI: 0.5, 0.9; p ¼ 0.039) domains, abnormality of Schirmer's test (RR ¼ 1.6, 95% CI: 1.3, 2.1; p < 0.0001) and salivary flow (RR ¼ 1.13, 95% CI: 1.0, 1.3; p ¼ 0.042). There was a significant association between anti-Ro60 and disease activity in the biological (RR ¼ 6.2, 95% CI: 2.7, 14.5; p < 0.0001) and cutaneous (RR ¼ 6.9, 95% CI: 1.0, 49.3; p ¼ 0.037) domains and Schirmer's test (RR ¼ 1.4, 95% CI: 1.1, 1.7; p ¼ 0.0001). A negative anti-Ro52 was significantly associated with fatigue visual analogue scores (p ¼ 0.034). Positive anti-Ro60 was significantly associated an elevated overall ESSDAI score (p ¼ 0.030). There was no significant association between antibody status and raynauds, renal, haematological, central nervous system, peripheral nervous system, muscular, glandular, liver or lymph node involvement, symptom duration, age or sex. Conclusions: The percentage of patients positive for both subtypes was similar in this cohort, in contrast to previous literature which showed a preponderance of anti-Ro52 in pSS. Anti-Ro-52 and anti-60 were associated with articular and cutaneous manifestations respectively. Positivity of either antibodies was associated with increased disease activity in the biological domains. Disclosure statement: All authors have declared no conflicts of interest. Background: Patients with musculoskeletal problems referred by GPs for physiotherapy often experience long delays before treatment. Some physiotherapy services have introduced a treatment pathway called PhysioDirect, involving initial telephone assessment and advice, with written self-management and exercise advice sent by post. Patients are invited for face-to-face treatment only when necessary. Our hypothesis was that PhysioDirect would be equally clinically effective compared with usual care, but more cost-effective, with increased patient satisfaction and shorter waits for treatment. Methods: Multi-centre pragmatic individually randomized trial comparing PhysioDirect versus usual care (patients join a waiting list and receive face-to-face care). PhysioDirect services were established in four PCTs. Adults with musculoskeletal problems, either self-referred for physiotherapy or referred from primary care, were invited to participate and randomized (by remote web-based allocation) to PhysioDirect or usual care. Outcome data were collected at baseline, 6 weeks and 6 months after randomization. Outcomes were collected by patient self-report and from medical records, blind to treatment allocation. The primary clinical outcome was SF36 PCS at 6 months; secondary outcomes included MYMOP, EQ5D, patient satisfaction, waiting times, time lost from work. Incremental cost-effectiveness was assessed using cost per QALY. Results: 2256 patients were recruited and randomized (1513 PhysioDirect, 743 Usual Care). 1921 (85%) were followed up at 6 months. PhysioDirect and usual care were equally clinically effective on our primary outcome (difference in mean PCS À0.01, 95% CI À0.80 to 0.79) and using the MYMOP measure (-0.02, 95% CI À0.16 to 0.11). Time to first assessment was 7 days for PhysioDirect compared to 34 days for Usual Care. Overall satisfaction appeared to be very slightly higher amongst those offered usual care (3.8% which equates to 0.19 points on a 6 point scale) which may not be meaningful. NHS costs were similar in the two arms (PhysioDirect £196.43 versus usual care £189.19, difference in means £19.30 (-£37.60 to £76.19)) while QALYs gained were also similar (difference in means 0.007 (-0.003 to 0.016)). Patients in PhysioDirect had a small but earlier improvement in health status than those in the Usual Care, achieved at an insignificantly greater cost. Incremental cost per QALY gained was £2889. Conclusions: A system of physiotherapy based on initial telephone and advice, offering face-to-face care only when necessary is equally clinically effective and broadly acceptable to patients compared with usual care. Although mean physiotherapy and total NHS costs were somewhat greater in PhysioDirect there was a gain in QALY compared to Usual Care due to more rapid improvement in patient outcomes. Table 1 shows the number of patients that reported having joint pain, the proportions of these that intended to, and subsequently did discuss joint pain, along with the diagnosis.
O30. THE CLINICAL RELEVANCE OF ANTI-RO52 AND ANTI-RO60 IN PATIENTS IN THE UNITED KINGDOM PRIMARY SJÖ GREN'S SYNDROME REGISTRY (UKPSSR)

Conclusions:
The prevalence of joint pain in patients consulting their GPs has not been reported previously, and the data presented here, albeit from a small sample, suggests that 49.3% of these patients aged 45 and over are experiencing joint pain. Data from local GP databases suggests that 14% of consultations in this age group relate to musculoskeletal symptoms, yet the data from this study suggests a higher proportion (21.3%). Furthermore, this study highlights that a number of patients intend to discuss joint pain but do not ultimately raise this concern with the GP (10.6%). Further aspects of this study which include qualitative analysis of the consultations and post consultation interviews with participants will provide a fuller picture of the pattern of consultation. Background: Symptomatic osteoarthritis (OA) is a major cause of disability. However, even among people with persistent, severe pain, many often do not consult their general practitioner (GP) about it over several years. Previous studies of the determinants of consultation for OA have focussed almost exclusively on patient characteristics and clinical need. Yet, given reports of patients' negative experiences and low expectations of healthcare services, their perceptions of what primary care has to offer will also be important. This study investigated the relative importance of service-related factors and clinical need factors in the decision to consult a GP for symptomatic OA. Methods: The design was a partial-profile choice-based conjoint analysis study based on a cross-sectional survey using a single postal self-complete questionnaire. Adults aged 50 years and over with hip, knee, or hand pain were identified from an existing population cohort study. Eligible potential participants were sent a postal self-complete questionnaire containing 10 choice tasks, each presenting two scenarios based on a combination of three out of six selected attributes (pain characteristics, pain disruption to everyday life, other current health problems, assessment/investigations available, treatment options available, and GP attitude). Multinomial logit regression (main effects) was used to estimate the relative importance patients placed on each of the attributes. Results represent the aggregate difference between the maximum and minimum utilities, expressed as logits, for each attribute level. Latent class analysis was used to identify subgroups of respondents with similar preferences. Results: 863 (74%) people responded (55% female) (mean age 70 years, range: 58-93). The most important determinant of the patient's decision to consult the GP for joint pain was the extent to which pain disrupted everyday life (1.10 logits). GP attitude (0.86) was perceived to be more important than the available treatments (0.45) or assessment/investigations (0.48). The decision to consult the GP for joint pain was less influenced by other health problems (0.46) and episodes of more severe, unpredictable pain (0.16). Subgroups identified by latent class appeared to be based more on differences in the strength of preferences overall than to differences in the relative importance of attributes per se. Conclusions: Service-related factors are as influential as the most important need-related determinant of consultation (i.e. disruption). Believing the GP would regard joint pain as 'part of the normal ageing process that one just has to accept' is a strong disincentive to seeking help, potentially outweighing other aspects of quality of care. Partialprofile conjoint methods are acceptable to respondents, wellcompleted, and can address attributes that are less accessible in traditional epidemiological designs. Disclosure statement: All authors have declared no conflicts of interest.
O35. ARE RHEUMATOID ARTHRITIS PATIENTS SCREENED FOR CARDIOVASCULAR DISEASE IN PRIMARY CARE?
Helen L. Background: The association between rheumatoid arthritis (RA) and increased risk of cardiovascular disease (CVD) is well recognized, reflected in EULAR and BSR guidance recommending cardiovascular screening in RA. Whether this is translated into routine clinical practice in primary care is less clear. The aim of this study was to compare rates of primary care CVD screening amongst RA patients and age, gender and practice-matched controls to determine if the additional cardiovascular risk associated with RA is being recognized and managed appropriately. Methods: This study was undertaken in two linked regional primary care databases: Consultations in Primary Care Archive (CiPCA) and Investigations in Primary Care Archive (IiPCA). All patients in the database with a diagnostic Read Code for RA between 2000 and 2008 and still registered with the practice in 2009 were identified and matched to 4 controls. CipCA and IiPCA were searched for records of blood pressure, body weight, smoking status, glucose and cholesterol monitoring during 2009 in both cases and controls. Results: 401 RA cases were identified and matched to 4 controls. Overall, the mean age was 58.7 years and 66% were female. No difference in screening between cases and controls was identified for blood pressure, body weight, cholesterol or glucose level. Increased screening for smoking status was apparent in RA patients (62% versus 67%) (95%CI 0.0%, 10.0%). The rate of screening for each risk factor was similar in males and females, but those aged over 65 years were more likely to be screened for any and for all risk factors (p < 0.0001). 352 (88%) RA patients had screening for at least 1 CVD risk factor compared to 985 (82%) controls (difference: 5.8% (95%CI 1.4%, 9.2%). The proportion having a comprehensive CVD screen (all 5 risk factors) was low (cases 25% versus controls 26%) and similar in cases and controls (p ¼ 0.648). Conclusions: Despite the well-known association between rheumatoid arthritis and cardiovascular disease such knowledge is not being translated into additional screening for people with rheumatoid arthritis. More emphasis needs to be placed on ensuring those with rheumatoid arthritis are actively screened for cardiovascular disease in primary care. 2012, 14.45 -16.15 iii37 
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